Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.3
Journals
JCM
Special Issues
Patient-Reported Outcomes (PROs) in Inflammatory Bowel Disease (IBD) Around the...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Patient-Reported Outcomes (PROs) in Inflammatory Bowel Disease (IBD) Around the World—2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 20 October 2026 | Viewed by 1575

Editor

Dr. Irina Blumenstein

E-Mail Website
Guest Editor
Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60594 Frankfurt am Main, Germany
Interests: inflammatory bowel disease; short bowel syndrome; colonoscopy; colorectal cancer screening
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following the success of the first edition of this Special Issue (https://www.mdpi.com/si/205569), we decided to launch a second edition to further expand the discussion on this important and rapidly evolving area.

For this new edition, we are thrilled to announce a call for manuscripts on the compelling topic of “Patient-Reported Outcomes (PROs) in Inflammatory Bowel Disease (IBD) Around the World” for publication in our journal. As the field of IBD research continues to evolve, there is a growing recognition for the importance of incorporating patient perspectives and experiences into clinical care and research.

Patient-Reported Outcomes (PROs) offer invaluable insights into the real-world impact of IBD on individuals’ lives, encompassing aspects such as symptom burden, quality of life, treatment satisfaction, and functional status. Understanding PROs is crucial for optimizing patient-centered care, enhancing treatment decision-making, and evaluating the effectiveness of interventions across diverse populations and healthcare settings.

We invite submissions that explore various dimensions of PROs in IBD, including, but not limited to, the following:

  1. Which PROs are routinely used in IBD?
  2. How is PRO reporting implemented in daily clinical routine?
  3. Best practice solutions for PRO reporting in different regions/countries.
  4. What are the strategies to incorporate patients’ views into therapeutic approaches?
  5. Which PROs reflect the psychosocial impact that IBD is having on QOL?
  6. Which diversity aspects are recognized in PRO reporting?
  7. Exploring regional differences in IBD patient care around the globe.
  8. Adding digital/AI tools to IBD patient care.

Dr. Irina Blumenstein
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • patient-reported outcomes
  • symptom burden
  • quality of life
  • treatment satisfaction

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1245 KB  
Article
Analgesic Use in Patients with Mild Inflammatory Bowel Disease—A Nationwide Cohort Study Based on Prescription Data
by Bente Mertz Nørgård, Caroline Theilgaard Thorarinsson, Kevin Erichsen Zeiss, Rahul S. Dalal, Mette Louise Andersen, Ken Lund, Sonia Friedman, Jens Kjeldsen and Torben Knudsen
J. Clin. Med. 2026, 15(8), 3121; https://doi.org/10.3390/jcm15083121 - 20 Apr 2026
Viewed by 605
Abstract
Background: In patients with Crohn’s disease (CD) and ulcerative colitis (UC) disease severity and activity have been associated with pain. Data on analgesic use in patients with mild disease, however, are limited. We examined prescribed analgesics in mild CD and UC. Methods: In [...] Read more.
Background: In patients with Crohn’s disease (CD) and ulcerative colitis (UC) disease severity and activity have been associated with pain. Data on analgesic use in patients with mild disease, however, are limited. We examined prescribed analgesics in mild CD and UC. Methods: In this cohort study, based on nationwide Danish prescription data, we identified incident patients (1996 through 2020) with mild CD (N = 5348) and UC (N = 15,622). Mild disease was defined by absence of advanced medical treatments, and no surgeries, in the period of 3.5 years after the diagnosis. We examined opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and paracetamol. We also examined opioid use in CD compared to UC. Results: In mild CD, the proportions of patients using analgesics in 2001 and 2020 were: strong/weak opioids 9.1% and 10.0%, chronic opioids 3.2% and 4.1%, NSAIDs 12.4% and 8.5%, and paracetamol 4.0% and 21.7%, respectively. In mild UC, the corresponding proportions in 2001 and 2020 were: strong/weak opioids 6.2% and 7.2%, chronic opioids 2.9% and 2.7%, NSAIDs 12.7% and 8.3%, and paracetamol 2.4% and 19.5%, respectively. The adjusted OR for chronic opioid use in mild CD relative to mild UC was 1.61 (95% CI 1.41–1.85). Conclusions: We found a widespread use of prescribed analgesics in patients with mild IBD. The trends across two decades were similar for both diseases: a steep increase in paracetamol, a modest decline in NSAIDs, a slight decline in weak opioids, but no decline in strong opioids. The risk of chronic opioid use was higher in mild CD than in mild UC. We suggest that patients with mild disease may have pain issues that need to be managed clinically. Full article
(This article belongs to the Special Issue Patient-Reported Outcomes (PROs) in Inflammatory Bowel Disease (IBD) Around the World—2nd Edition)
►▼ Show Figures

Graphical abstract

14 pages, 236 KB  
Article
Outcomes of Percutaneous Coronary Intervention in Patients with Inflammatory Bowel Disease
by Umesh Bhagat, Akshat Banga, Ankit Agrawal, Prabhat Kumar, Aro Daniela Arockiam, Akiva Rosenzveig, Danial Nasif, Heba Wassif and Jean-Paul Achkar
J. Clin. Med. 2026, 15(6), 2431; https://doi.org/10.3390/jcm15062431 - 22 Mar 2026
Viewed by 698
Abstract
Background: Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), has been associated with elevated cardiovascular risks. However, the impact of IBD on outcomes following percutaneous coronary intervention (PCI) remains underexplored. We aimed to evaluate the clinical and procedural outcomes [...] Read more.
Background: Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), has been associated with elevated cardiovascular risks. However, the impact of IBD on outcomes following percutaneous coronary intervention (PCI) remains underexplored. We aimed to evaluate the clinical and procedural outcomes of PCI in patients with concurrent IBD. Methods: This study utilized the National Readmission Database from 2016 to 2020 to evaluate outcomes such as all-cause mortality and post-PCI complications, including various cardiovascular and gastrointestinal (GI) complications in IBD patients undergoing PCI. Patients with concurrent IBD and PCI were compared to non-IBD controls via multivariable logistic regression. Results: On propensity-score-matching analysis, IBD patients undergoing PCI had a higher prevalence of GI complications, including acute liver failure (Odds ratio (OR) 1.48, 95% confidence interval (CI) 1.13–1.93, p = 0.004), mesenteric ischemia (OR 5.34, 95% CI 1.56–18.40, p = 0.007), and need for blood transfusion (OR 1.74, 95% CI 1.46–2.08, p < 0.001). There was also a higher rate of cardiac complications (OR 1.31, 95% CI 1.05–1.64, p = 0.017). No significant difference in all-cause mortality (OR 0.86, 95% CI 0.72–1.04, p = 0.113) was observed. Conclusions: IBD patients undergoing PCI face increased GI and cardiovascular complications without a significant mortality difference. These findings highlight the complex interplay between systemic inflammation, vascular integrity, and procedural outcomes in IBD patients. Full article
(This article belongs to the Special Issue Patient-Reported Outcomes (PROs) in Inflammatory Bowel Disease (IBD) Around the World—2nd Edition)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop